Kornimate/medical-research-clean huggingface dataset:
proprioceptive postural control and diaphragm paresis

Conditions: Proprioceptive Postural Control; Respiratory Disorders; Chronic Obstructive Pulmonary Disease

Summary: proprioceptive weighting changes may explain differences in postural control performance. in addition, the respiratory movement has a disturbing effect on postural balance. postural balance seems to be impaired in individuals with respiratory disorders. increased risk of falling is reported in individuals with chronic obstructive pulmonary disease. besides the essential role of respiration, the diaphragm may also play an important role in the control of the trunk and postural balance. the aim of the study is to clarify whether proprioceptive postural control is impaired in individuals with diaphragm paresis.


Eligibility criteria:
inclusion criteria individuals with diaphragm paresis: * age: 18-70 years old * unilateral or bilateral diaphragm paresis following paresis of phrenic nerve * willingness to sign the informed consent inclusion criteria healthy controls: * age: 18-70 years old * spirometry: fev1/fvc ≥ 0.7 and fev1 \> 80% * willingness to sign the informed consent exclusion criteria: * history of major trauma and/or major orthopedic surgery of the spine, the pelvis or the lower quadrant * one of the following conditions: parkinson, multiple sclerosis, stroke, history of vestibular disorder * respiratory disorder other than diaphragm paresis * recent diagnosis of cancer * significant cardiovascular comorbidity
metastatic pathologic fractures, short term results

Conditions: Pathologic Fracture; Bone Metastases; Metastatic Cancer

Summary: this is a single center prospective study to compare the short term results of prosthesis, nail and plate-screw surgeries for metastatic pathologic fractures.

the most common bone tumor in elderly is metastatic bone tumors. with the prolonged life expectancy in cancer patients, the management of the metastases became an essential topic. pathological fractures should be examined and managed with a different perspective. they usually cannot be healed by conservative methods and require surgical intervention. the primary goals of surgical intervention are to relieve pain and mobilize the patient as soon as possible. the aim of the study is to compare the short-term functional endoprosthetic recontruction, intramedullary nailing and open reduction internal fixation. the primary tumor of the patient, applied chemotherapy and radiotherapy, mirel risk score, charlson comorbidity index, and pathfx 3.0 survival will be evaluated preoperatively. the type of the operation will be decided at the multidisciplinary tumor council of ankara university.

Eligibility criteria:
inclusion criteria: * metastatic pathologic fracture * operated via endoprosthesis, intramedullary nail or plate \& screws exclusion criteria: * primary bone tumor * conservative management * neuromuscular disease * periprosthetic fractures * less than 1 month follow up

Keywords: bone metastasis pathologic fracture endoprosthetic reconstruction intramedullary nailing open reduction internal fixation plate and screws
evaluation of the neurologic assessment in pediatric neuro-oncology (pnano)

Conditions: Pediatric Brain Tumor; Pediatric Spine Tumor

Summary: this study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors.

this study is designed to evaluate inter-observer variability of the pnano scale when implemented during routine clinic visits for pediatric brain and spine tumor patients. typically, during a routine clinic visit for patients with pediatric brain and spine tumors, a neurological examination is completed and documented by a provider in clinic notes under the section 'physical examination', sub-heading 'neurologic examination.' for this study, every participant will have neurologic examinations performed by 2 or 3 (if feasible), separate providers on the same day (patient's scheduled provider and one or two additional providers from the study team), during a scheduled, routine clinic visit(s). to allow for potential significant discrepancies in exams between two providers, if feasible, a third provider will complete an examination at each visit. each provider will independently perform the neurologic examination and will document the findings on the pnano scale scorecard. each provider will also record the amount of time it took to complete their neurologic examination. the providers will not communicate with each other about the findings and will be completely blinded to each other's evaluations. the pnano scale will be completed at a second clinic visit, between 1-6 months out from the initial assessment. telemedicine visit evaluations will be allowed for 20% of patients enrolled on study to assess if this scale is feasible via telemedicine. for telemedicine visits, one provider will need to be in clinic to complete the first examination and the second provider will be virtual to complete the second examination on the same day. a third provider would need to be in clinic to complete an examination. for the second evaluation 1-6 months after the first, the same will apply, one or two providers in clinic to complete the first examination while the second/third provider will be virtual. providers can include physicians and advanced practice providers of any subspecialty: neurology, hematology-oncology, radiation oncology, neurosurgery, physical medicine and rehabilitation.

Eligibility criteria:
inclusion criteria: * greater than or equal to 1 year old * must be seen in the pediatric clinic * radiographic or histologic confirmation of a brain or spine tumor at the time of initial diagnosis * patient or parent/guardian must be able to understand the consent and be willing to sign a written informed consent document according to institutional guidelines. exclusion criteria: * none specified
early detection of atrial fibrillation in patients with transient ischemic attack

Conditions: Transient Ischemic Attack; Atrial Fibrillation

Summary: the purpose of this study is to determine the frequency of atrial fibrillation in patients with transient ischemic attack (tia). patients suffering tia will have their heart rhythm extensively monitored with 72-hour holter-monitoring and an implantable loop-recorder. furthermore, the patients will be examined with echocardiography, coronary calcium-score and biomarkers with the purpose to predict which subjects at risk for developing atrial fibrillation.

stroke is a leading cause of death and the survivors are often left with severe disability. transient ischemic attack (tia) is an episode of neurological dysfunction, but unlike stroke, the neurological deficits resolve completely within 24 hours. tia and stroke share the same common underlying cause, and patients with a tia are at high risk for developing a subsequent stroke. atrial fibrillation (af) is the most common cardiac arrhythmia and is recognized as the cause of around 25% of all strokes. the prevalence of af rises with age, and it is estimated, that approximately 5-10% of all subjects over the age of 80 years has either persistent or paroxysmal af. regardless of the af subtype the risk for stroke is the same, and oral anticoagulation therapy is recognized as a superior treatment of af related stroke/tia. the goal of this project is to extend the normal workup of patients with tia with a thorough heart monitoring program. this includes 72-hours ambulatory electrocardiogram and insertion of an implantable loop recorder (ilr). the ilr is small device implanted in the subcutaneous tissue in the left thoracic region. the device continuously monitors for arrhythmias in a period up to 3 years. the 150 patients enrolled will also receive an ultrasound examination of the heart and arteries of the neck and a computed tomography scan of the heart. lastly, biomarkers with known or suspected association with stroke and af will be measured. the primary goal of the study is to determine, whether or not an extended heart monitoring program with an ilr will identify more patients with af as the underlying cause of tia. this can have enormous advantages for the patient, because the treatment with oral anticoagulation therapy reduces the risk of subsequent stroke by approximately 40% compared to conventional antiplatelet therapy. secondly, the study means to identify patients at high risk for developing af assessed with ultrasound, computed tomography and novel biomarkers.

Eligibility criteria:
inclusion criteria: * diagnosed with tia by a board certified neurologist * written consent * residents of funen, denmark or surrounding islands exclusion criteria: * prior stroke * known atrial fibrillation * known contraindication for anticoagulant therapy * patients already in anticoagulant therapy * patients with estimated short life expectancy * pregnancy * prior tia with known etiology

Keywords: transient ischemic attack atrial fibrillation notice implantable loop-recorder holter-monitoring
safety and tolerability study of larazotide acetate in celiac disease subjects

Conditions: Celiac Disease

Summary: this study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.

clin1001-004 was a randomized, double-blind, placebo controlled, dose-ranging, 7-arm, multicenter study with a gluten challenge. the objects were multiple dose safety and tolerance; efficacy (intestinal permeability \[change in urinary lama ratio\] and disease signs and symptoms) following gluten challenge. following a 21-day screening period, subjects were randomized to one of seven treatments groups: four groups received larazotide acetate (0.25 mg, 1 mg, 4 mg or 8 mg tid) along with an 800 mg gluten challenge, one group received placebo with an 800 mg gluten challenge, a safety control arm received the highest dose of larazotide acetate (8 mg tid) and gluten placebo and the last group received drug placebo and gluten placebo. the gluten challenge was administered as capsules (800 mg tid) with each main meal for a total of 2.4 g daily. drug or drug placebo was administered tid 15 minutes prior to each main meal. subjects received their assigned treatments for two weeks (day 0 through day 14) and came to clinic for a follow-up visit one week later (day 21). subjects remained on their gluten-free diet for the duration of the study.

Eligibility criteria:
inclusion criteria: * must have been diagnosed with celiac disease by biopsy for ≥ 6 months. * have a anti-tissue transglutaminase (ttg) ≤ 10 eu as measured by serology. * must be on a gluten-free diet for at least the past 6 months. exclusion criteria: * have any chronic active gi disease other than celiac disease (e.g., ibs, crohn's, colitis). * have diabetes (type 1 or type 2). * chronically consumes non-steroidal anti-inflammatory agents ("nsaids") or takes proton-pump inhibitors. * consuming oral corticosteroids or immune suppressants.

Keywords: larazotide acetate
non-invasive optical detection of iron deficiency in children

Conditions: Iron Deficiency; Iron-deficiency Anemia; Child

Summary: this study aims to evaluate a prototype device detecting zinc protoporphyrin-ix fluorescence non-invasively from the intact oral mucosa in children. the prototype device has shown high sensitivity and specificity in women after delivery for iron deficiency. children are at increased risk for iron deficiency and prevention methods are not established jet. zinc protoporphyrin-ix is an early indicator of iron deficiency and may be more sensitive than other established parameters. the prototype device is used to measure the erythrocyte zinc protoporphyrin-ix/heme ratio in children aged 9 months to 5 years. children in this age are at increased risk for iron deficiency as they are growing rapidly and iron deficiency in this age may affect the neurodevelopment and immune system adversely. it is proposed that these effects cannot be rectified by iron supplementation in later years. the results from the non-invasive measurements are compared to reference measurements of the erythrocyte zinc protoporphyrin-ix/heme ratio from residual blood samples from the same patients and to other indicators of iron status, including hemoglobin, ferritin, serum iron, transferrin, transferrin saturation and soluble transferrin receptor.

this trial is a proof-of-concept study using a prototype fiber optic fluorometer to acquire autofluorescence spectra in children aged 9 months to 5 years and determine the erythrocyte zinc protoporphyrin-ix fluorescence intensity from these spectra. the non-invasively determined fluorescence spectra are evaluated to provide a quantitative measure of the erythrocyte zinc protoporphyrin-ix/heme concentration ratio. these values are primarily compared to an erythrocyte zinc protoporphyrin-ix determined by hplc from residual blood samples from the same subjects and secondarily to erythrocyte zinc protoporphyrin-ix/heme ratios determined using a commercial hematofluorometer (aviv, model 206d) and other indicators of iron status, including hemoglobin, ferritin, serum iron, transferrin, transferrin saturation and soluble transferrin receptor this study could help to establish the non-invasive fluorescence measurement of zinc protoporphyrin-ix as a rapid, easy to use means for point-of-care screening for iron deficiency in resource-limited settings lacking laboratory infrastructure.

Eligibility criteria:
inclusion criteria: * children aged 9 months to 5 years * planed blood sampling, independently from this study * informed written consent to participation´s guardian in the study exclusion criteria: * the ability of the guardian is not given to approve the consent * transfusion of blood products before entering the study * blood sampling is not planed for clinical investigations

Keywords: iron deficiency child infancy preschool children iron deficiency anemia
efficacy of 0.2 % digluconate chlorhexidine mouthwash for preventing alveolar osteitis after third molar extraction

Conditions: Alveolar Osteitis

Summary: the purpose of this study is to demonstrate the efficacy of 0.2 % digluconate chlorhexidine mouthwash in the prevention of alveolar osteitis following third molar extraction and to evaluate the safety and local tolerability.


Eligibility criteria:
inclusion criteria: * male or female over 18 years old * subject needing to undergo extraction of one impacted mandibular third molar * for woman of childbearing potential and woman in post menopausal period under hormonal substitution treatment, she must accept to plan the extraction of the impacted mandibular third molar only during the last week of the menstrual cycle. * affiliated to a social security system, or is a beneficiary (if applicable in the national regulation) exclusion criteria: * existence or history of parotid gland disorders * acute or history of recent acute pericoronitis at any tooth * extraction of more than 1 third molar in the same surgical procedure * subject at high risk of bacterial endocarditis (prosthetic heart valve, history of bacterial endocarditis, congenital cyanogenic heart disease) * coagulation or haemostatic disorder or use of anticoagulants * hypersensitivity to chlorhexidine or any of the excipients; * hypersensitivity to any anesthetic agent; * hypersensitivity to corticosteroids, analgesics including opioid drugs used for post-surgery pain relief * intake of systemic vasodilator or vasoconstrictor * intake of systemic or local (in the mouth) antibiotics within 7 days before day 1 and/or any pre- or post-operative antibiotic prophylaxis planned to be prescribed during the study; * use of any antiseptic mouthwash within 7 days before day -1 * regular heavy smokers (more than 20 cigarettes per day) * is pregnant or in post-partum period or a nursing mother

Keywords: alveolar osteitis third molar dry socket mouthwash third molar extraction
treatment intervention of patients with carpal tunnel syndrome (cts)

Conditions: Carpal Tunnel Syndrome

Summary: the purpose of this study was to investigate the effectiveness of kt versus tens combining self-myofascial stretching in treatment of cts through clinical, functional assessment and sensory measurements. primary hypothesis the kt group has a more substantial improvement in hand grip, pain relief, enhancing proprioceptive sensitivity and dexterity compare to the tens group. treatment program,

objective: to compare the effectiveness of a home-based treatment program involving kinesio taping (kt) or transcutaneous electrical nerve stimulation (tens) among carpal tunnel syndrome (cts) patients. methods: 30 participants with cts were enrolled, age range, 30 to 60 years. the participants who met the inclusion criteria were randomized into one of two treatment groups: kt group and tens group. participants were blinded to the treatments used in the other group. patients with cts received aforementioned treatments compared with reliable qualitative and quantitative evaluation tools before and after 4-week treatment, as well as at a additional 4-week follow-up. the main parameters include the symptom severity scale (sss) and functional status scale (fss), hand grip and key pinch strengths, two-point discrimination (2pd), modified moberg pick-up test (mmput), and pain assessment (visual analog scale, vas).

Eligibility criteria:
inclusion criteria: * numbness and tingling in the median nerve territory of the hand. * nocturnal paresthesia. * induction test (tinel's sign and phalen's test) showing a positive finding., * is defined as mild and moderate cts according to nerve conduction studies (ncss). exclusion criteria: * is defined severe cts symptoms. * are currently pregnant or have any secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism, previous wrist trauma). * cervical radiculopathy or polyneuropathy. * previous history of carpal tunnel decompression surgery. * corticosteroid injection into the carpal tunnel.

Keywords: carpal tunnel syndrome home-based treatment program kinesio taping paresthesia thenar eminence
suture techniques to reduce the incidence of the incisional hernia

Conditions: Hernia; Wound Infection; Burst Abdomen; Pain; Quality of Life

Summary: the objective of the study is reduction of the incidence of the most frequent complication of abdominal surgery, incisional hernia. in this multi center double-blinded prospective randomized controlled trial, in which a new suture technique using small bites is compared with the traditionally applied large bites (mass closure) technique for midline incisions.


Eligibility criteria:
inclusion criteria * signed informed consent * all laparotomies with a midline incision * age \> 18 years exclusion criteria * previous incisional hernia after midline incision * previous surgery through a midline incision within 3 months * pregnancy (in women)

Keywords: surgery incisional hernia woundinfection burst abdomen pain
safety and efficacy of baffr cart for relapsed/ refractory neuromyelitis optica spectrum disorder

Conditions: Neuromyelitis Optica Spectrum Disorder

Summary: this is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory neuromyelitis optica spectrum disorders (nmosd). the aim is to evaluate the safety and efficacy of the treatment with baffr cart.


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged 18-60 years; 2. patients must be diagnosed as aqp4-igg-positive nmosd; 3. at least one immunosuppressant has been used for over a year with poorly controlled symptoms; 4. clinical evidence of at least two relapses in the last 12 months or three relapses in the last 24 months and one relapse in the preceding 12 months before screening. 5. subjects and their partners must be willing to use effective and reliable methods of contraception, devices or medicines, within one year before baffr cart cells infusion. 6. subjects must provide written informed consent before the study begins and comply with the requirements of the study protocol. exclusion criteria: 1. subjects have received b cell deletion treatment within 6 months before screening; 2. chronic and active hepatitis b (hbv), hepatitis c (hcv), human immunodeficiency virus (hiv) infection, cmv or syphilis infections concurrently. 3. subjects with papovaviruses infection. 4. subjects have received live attenuated vaccine vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment; 5. history of psychoactive drug abuse and failed to withdraw, or have a history of psychiatric disorders. 6. pregnant or lactating women. 7. subjects with severe heart, liver, kidney or bone marrow function disorder. 8. allergic constitution or a history of severe allergies. 9. subjects with conditions adjudicated by the investigator as unsuitable for lymphodepletion or cell infusion.
a study on changes in ifn-gamma levels following anti-tnf treatment in patients undergoing serial quantiferon-tb gold in-tube

Conditions: Inflammatory Rheumatic Diseases

Summary: the screening for latent tuberculosis infection (ltbi) prior to the onset of anti-tumor necrosis factor therapy, as well as a watchful monitoring during the treatment, is strongly recommended. tuberculin skin test (tst), universally used for this purpose, lacks sensitivity and specificity. the novel screening tools, including quantiferon-tb gold in-tube (qft-git), have shown a higher specificity compared to tst, but their feasibility in the setting of immunosuppression remains unclear. aims of this study were to investigate the performance of qft-git and its agreement with tst in patients awaiting anti-tumor necrosis factor (tnf) therapy, and to evaluate the usefulness of serial qft-git during the treatment with biologics to assess whether dynamic changes in interferon (ifn)-gamma levels may be helpful in identifying reactivation of ltbi or cases of newly acquired tuberculosis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of inflammatory rheumatic diseases * patients candidates to anti-tnf treatment exclusion criteria:

Keywords: anti-tnf tuberculosis quantiferon-tb gold in-tube tuberculin skin test rheumatoid arthritis spondyloarthritis